Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
ADAMS, Brad
To:ACell Inc., VP, Sales (August)
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
From solving delivery challenges for Moderna's COVID-19 vaccine to pioneering the next generation of programmable medicines, the 2025 Rising Leader provides mid-career reflections.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
June Raine was a “hard act to follow” at MHRA, but new chief executive Lawrence Tallon is looking to the future in setting out a vision for the UK regulator.
The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.
The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.
Seven $1bn+ alliances were penned in August, and two exceeded $2bn.
With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.
